533 related articles for article (PubMed ID: 34531847)
21. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
22. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.
Leung J; Suh WK
Immune Netw; 2014 Dec; 14(6):265-76. PubMed ID: 25550693
[TBL] [Abstract][Full Text] [Related]
23. Targeting the B7 family of co-stimulatory molecules: successes and challenges.
Podojil JR; Miller SD
BioDrugs; 2013 Feb; 27(1):1-13. PubMed ID: 23329394
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of B7-CD28 costimulation in urologic malignancies.
Thompson RH; Kwon ED; Allison JP
Immunotherapy; 2009 Jan; 1(1):129-39. PubMed ID: 20445772
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
26. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
27. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N
Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701
[TBL] [Abstract][Full Text] [Related]
28. Anticancer natural products targeting immune checkpoint protein network.
Chun KS; Kim DH; Raut PK; Surh YJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
[TBL] [Abstract][Full Text] [Related]
29. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
Front Immunol; 2019; 10():491. PubMed ID: 30936880
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of immune checkpoint molecules in breast cancer.
Fang J; Chen F; Liu D; Gu F; Chen Z; Wang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32602545
[TBL] [Abstract][Full Text] [Related]
31. VISTA: Coming of age as a multi-lineage immune checkpoint.
ElTanbouly MA; Schaafsma E; Noelle RJ; Lines JL
Clin Exp Immunol; 2020 May; 200(2):120-130. PubMed ID: 31930484
[TBL] [Abstract][Full Text] [Related]
32. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
33. Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy.
Amir Taghavi B; Alizadeh N; Saeedi H; Karim Ahangar N; Derakhshani A; Hajiasgharzadeh K; Silvestris N; Baradaran B; Brunetti O
Molecules; 2022 May; 27(11):. PubMed ID: 35684481
[TBL] [Abstract][Full Text] [Related]
34. CD28/B7 costimulation: a review.
Greenfield EA; Nguyen KA; Kuchroo VK
Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
[TBL] [Abstract][Full Text] [Related]
35. [CD28 costimulation and checkpoint inhibition in T cells].
Beyersdorf N; Kerkau T
Internist (Berl); 2020 Jul; 61(7):652-659. PubMed ID: 32462247
[TBL] [Abstract][Full Text] [Related]
36. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
Chen X; Song X; Li K; Zhang T
Front Immunol; 2019; 10():292. PubMed ID: 30863404
[TBL] [Abstract][Full Text] [Related]
37. A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
Zheng S; Luo X; Dong C; Zheng D; Xie J; Zhuge L; Sun Y; Chen H
Int J Cancer; 2018 Nov; 143(10):2592-2601. PubMed ID: 30152019
[TBL] [Abstract][Full Text] [Related]
38. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
40. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
